JP2020037585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020037585A5 JP2020037585A5 JP2019206852A JP2019206852A JP2020037585A5 JP 2020037585 A5 JP2020037585 A5 JP 2020037585A5 JP 2019206852 A JP2019206852 A JP 2019206852A JP 2019206852 A JP2019206852 A JP 2019206852A JP 2020037585 A5 JP2020037585 A5 JP 2020037585A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- orally acceptable
- acceptable dosage
- formulation
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 15
- 238000009472 formulation Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- -1 hydroxy piperidinylmethyl Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000008467 tissue growth Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 CN(C(*)=*)NC(C=C[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O Chemical compound CN(C(*)=*)NC(C=C[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O 0.000 description 4
- BGUKCLNXSXSYCZ-PLNGDYQASA-N CC(C)(C)C(NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O)=O Chemical compound CC(C)(C)C(NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O)=O BGUKCLNXSXSYCZ-PLNGDYQASA-N 0.000 description 1
- XDEHMKQLKPZERH-BYPYZUCNSA-N CC(C)[C@@H](C(N)=O)N Chemical compound CC(C)[C@@H](C(N)=O)N XDEHMKQLKPZERH-BYPYZUCNSA-N 0.000 description 1
- QZXFTDAXYQVJOG-ARJAWSKDSA-N CC1N(CC(NNC2OC2/C=C\[n]2nc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)nc2)=O)C(C)COC1 Chemical compound CC1N(CC(NNC2OC2/C=C\[n]2nc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)nc2)=O)C(C)COC1 QZXFTDAXYQVJOG-ARJAWSKDSA-N 0.000 description 1
- JGZRCCPXJBIBJL-PLNGDYQASA-N CN(C(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O)[N](C)(C)C(C(N1CCOCC1)=O)=O Chemical compound CN(C(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O)[N](C)(C)C(C(N1CCOCC1)=O)=O JGZRCCPXJBIBJL-PLNGDYQASA-N 0.000 description 1
- WPZLXGTWFVZICP-XQRVVYSFSA-N CNC(CN(CC1)CC[O]1/[O]=C(\C1CNCCC1)/NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O)=O Chemical compound CNC(CN(CC1)CC[O]1/[O]=C(\C1CNCCC1)/NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O)=O WPZLXGTWFVZICP-XQRVVYSFSA-N 0.000 description 1
- ODDMRWATJPOZIC-IHWYPQMZSA-N Cc([nH]nc1)c1C(NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O)=O Chemical compound Cc([nH]nc1)c1C(NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O)=O ODDMRWATJPOZIC-IHWYPQMZSA-N 0.000 description 1
- CSDUVPJWQLJHGC-UHFFFAOYSA-O O=C(C=C[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)N[NH2+]C(c1nccnc1)=O Chemical compound O=C(C=C[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)N[NH2+]C(c1nccnc1)=O CSDUVPJWQLJHGC-UHFFFAOYSA-O 0.000 description 1
- OVOIZHFSFHOUPO-UPHRSURJSA-N O=C(CN1CCOCC1)NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O Chemical compound O=C(CN1CCOCC1)NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O OVOIZHFSFHOUPO-UPHRSURJSA-N 0.000 description 1
- FEWZCLGKEHFXRY-RJRFIUFISA-N O=C(Cc1cnccn1)NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O Chemical compound O=C(Cc1cnccn1)NNC(/C=C\[n]1nc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1)=O FEWZCLGKEHFXRY-RJRFIUFISA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644802P | 2012-05-09 | 2012-05-09 | |
| US61/644,802 | 2012-05-09 | ||
| US201361798188P | 2013-03-15 | 2013-03-15 | |
| US61/798,188 | 2013-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018154275A Division JP2018172444A (ja) | 2012-05-09 | 2018-08-20 | 核内輸送調節因子およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218700A Division JP2021063104A (ja) | 2012-05-09 | 2020-12-28 | 核内輸送調節因子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020037585A JP2020037585A (ja) | 2020-03-12 |
| JP2020037585A5 true JP2020037585A5 (OSRAM) | 2020-05-14 |
| JP6818849B2 JP6818849B2 (ja) | 2021-01-20 |
Family
ID=49448240
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511713A Active JP6195909B2 (ja) | 2012-05-09 | 2013-05-09 | 核内輸送調節因子およびその使用 |
| JP2017160341A Withdrawn JP2018012715A (ja) | 2012-05-09 | 2017-08-23 | 核内輸送調節因子およびその使用 |
| JP2018154275A Withdrawn JP2018172444A (ja) | 2012-05-09 | 2018-08-20 | 核内輸送調節因子およびその使用 |
| JP2019206852A Active JP6818849B2 (ja) | 2012-05-09 | 2019-11-15 | 核内輸送調節因子およびその使用 |
| JP2020218700A Withdrawn JP2021063104A (ja) | 2012-05-09 | 2020-12-28 | 核内輸送調節因子およびその使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511713A Active JP6195909B2 (ja) | 2012-05-09 | 2013-05-09 | 核内輸送調節因子およびその使用 |
| JP2017160341A Withdrawn JP2018012715A (ja) | 2012-05-09 | 2017-08-23 | 核内輸送調節因子およびその使用 |
| JP2018154275A Withdrawn JP2018172444A (ja) | 2012-05-09 | 2018-08-20 | 核内輸送調節因子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218700A Withdrawn JP2021063104A (ja) | 2012-05-09 | 2020-12-28 | 核内輸送調節因子およびその使用 |
Country Status (32)
| Country | Link |
|---|---|
| US (10) | US9266843B2 (OSRAM) |
| EP (3) | EP3404027B1 (OSRAM) |
| JP (5) | JP6195909B2 (OSRAM) |
| KR (5) | KR102163377B1 (OSRAM) |
| CN (1) | CN104428295B (OSRAM) |
| AU (5) | AU2013259384B2 (OSRAM) |
| BR (1) | BR112014027860B8 (OSRAM) |
| CA (1) | CA2872190C (OSRAM) |
| CL (1) | CL2014003054A1 (OSRAM) |
| CO (1) | CO7190242A2 (OSRAM) |
| CY (2) | CY1120832T1 (OSRAM) |
| DK (2) | DK3404027T3 (OSRAM) |
| EA (1) | EA036639B1 (OSRAM) |
| ES (3) | ES2702279T3 (OSRAM) |
| GE (1) | GEP20237477B (OSRAM) |
| HR (2) | HRP20181838T1 (OSRAM) |
| HU (2) | HUE050452T2 (OSRAM) |
| IN (1) | IN2014DN09434A (OSRAM) |
| LT (2) | LT2858991T (OSRAM) |
| ME (1) | ME03795B (OSRAM) |
| MX (1) | MX364992B (OSRAM) |
| NZ (1) | NZ702663A (OSRAM) |
| PE (1) | PE20150128A1 (OSRAM) |
| PL (2) | PL3404027T3 (OSRAM) |
| PT (2) | PT2858991T (OSRAM) |
| RS (2) | RS60424B1 (OSRAM) |
| SG (1) | SG11201407268SA (OSRAM) |
| SI (2) | SI2858991T1 (OSRAM) |
| SM (2) | SMT201800686T1 (OSRAM) |
| UA (2) | UA124922C2 (OSRAM) |
| WO (1) | WO2013170068A2 (OSRAM) |
| ZA (1) | ZA202004892B (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011109799A1 (en) | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| CA2824808A1 (en) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| PL2736887T3 (pl) | 2011-07-29 | 2018-03-30 | Karyopharm Therapeutics, Inc. | Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania |
| BR112014001933A2 (pt) | 2011-07-29 | 2017-02-21 | Karyopharm Therapeutics Inc | moduladores de transporte nuclear e usos dos mesmos |
| PT2858991T (pt) * | 2012-05-09 | 2018-12-17 | Biogen Ma Inc | Moduladores do transporte nuclear e usos dos mesmos |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| RS60244B1 (sr) | 2013-01-15 | 2020-06-30 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| WO2014144772A1 (en) * | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| RS58581B1 (sr) | 2013-06-21 | 2019-05-31 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori jedarnog transporta i njihova primena |
| WO2014205393A1 (en) * | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2015027124A1 (en) | 2013-08-23 | 2015-02-26 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| EP3143627B1 (en) * | 2014-05-13 | 2018-07-11 | QSA Global Inc. | Device and method for enhanced iridium gamma radiation sources |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| CN111484483B (zh) | 2014-08-15 | 2023-05-26 | 卡尔约药物治疗公司 | 赛灵克斯的多晶型物 |
| KR101734529B1 (ko) | 2015-05-08 | 2017-05-11 | 건국대학교 산학협력단 | 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물 |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| US20200216906A1 (en) * | 2015-08-25 | 2020-07-09 | President And Fellows Of Harvard College | Methods and compositions relating to the diagnosis and treatment of cancer |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017117535A1 (en) * | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| EP3423468A4 (en) * | 2016-02-29 | 2019-10-23 | Ohio State Innovation Foundation | AZA PEPTIDE ALDEHYDE AND KETONE |
| EP3429690A4 (en) * | 2016-03-16 | 2019-10-23 | Ionis Pharmaceuticals, Inc. | METHOD FOR MODULATING KEAP1 |
| WO2017190087A1 (en) | 2016-04-30 | 2017-11-02 | Envision Diagnostics, Inc. | Medical devices, systems, and methods for performing eye exams and eye tracking |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| JP7167168B2 (ja) | 2018-01-10 | 2022-11-08 | エックスダブリューファルマ リミテッド | ケタミンのプロドラッグ、組成物及びそれらの使用 |
| WO2019232724A1 (en) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| WO2020092965A1 (en) * | 2018-11-01 | 2020-05-07 | Karyopharm Therapeutics Inc. | E2f1 as a biomarker for treatments using xpo1 inhibitors |
| CA3121749A1 (en) | 2018-12-06 | 2020-06-11 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| CN111606890A (zh) * | 2019-02-26 | 2020-09-01 | 微境生物医药科技(上海)有限公司 | 含丙烯酰基的核转运调节剂及其用途 |
| CN109928939A (zh) * | 2019-02-27 | 2019-06-25 | 上海卡洛化学有限公司 | 一种2,2,6,6-四甲基吗啉的制备方法 |
| CR20210590A (es) * | 2019-05-01 | 2022-03-11 | Karyopharm Therapeutics Inc | Proceso para la preparación de inhibidores de xpo1 y productos intermedios para su uso en la preparación de inhibidores de xpo1 |
| CN111145135B (zh) * | 2019-12-30 | 2021-08-10 | 腾讯科技（深圳）有限公司 | 一种图像去扰处理方法、装置、设备及存储介质 |
| DE112022001910T5 (de) | 2021-04-01 | 2024-01-25 | Alps Alpine Co., Ltd. | Vorrichtung zur erkennung einer betätigung |
| MX2023012427A (es) * | 2021-04-21 | 2024-02-09 | Natco Pharma Ltd | Proceso mejorado para la preparacion de derivados de 7-(morfolinil)-2-(n-piperazinil) metiltieno [2,3-c] piridina. |
| JP7737544B2 (ja) | 2021-08-13 | 2025-09-10 | エックスダブリューファーマ リミテッド | ケタミン誘導体の医薬組成物及び経口剤形 |
| WO2023172855A2 (en) * | 2022-03-07 | 2023-09-14 | Kaohsiung Medical University | Methods for treating hepatitis b virus infection |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017398A (en) | 1911-01-16 | 1912-02-13 | John E Folsom | Telegraph-key. |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5468353A (en) | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
| BR9509760A (pt) | 1994-11-23 | 1998-06-30 | Neurogen Corp | Composto |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| AU2178497A (en) | 1996-04-04 | 1997-10-29 | Shionogi & Co., Ltd. | Cephem compounds and drugs containing the compounds |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| PT913392E (pt) | 1996-04-25 | 2003-11-28 | Nissan Chemical Ind Ltd | Derivados de etileno e agentes pesticidas |
| DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| AU2960599A (en) | 1998-03-30 | 1999-10-18 | Akira Karasawa | Quinazoline derivatives |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| EP1335898B1 (en) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| JP3608050B2 (ja) | 2001-07-24 | 2005-01-05 | トヨタ自動車株式会社 | ロールオーバ判別装置 |
| CN1578663B (zh) | 2001-09-14 | 2011-05-25 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
| WO2004037248A2 (en) | 2002-10-24 | 2004-05-06 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| PL376733A1 (pl) | 2002-11-01 | 2006-01-09 | Takeda Pharmaceutical Company Limited | Środek do zapobiegania lub leczenia neuropatii |
| ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| CA2512886A1 (en) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| BRPI0511504A (pt) | 2004-05-26 | 2008-01-22 | Eisai R&D Man Co Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides |
| CN101014595A (zh) | 2004-08-11 | 2007-08-08 | 杏林制药株式会社 | 新型环状氨基苯甲酸衍生物 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| US20100130737A1 (en) | 2005-02-18 | 2010-05-27 | Takeda Pharmaceutical Company Limited | Regulating Agent of GPR34 Receptor Function |
| US8637559B2 (en) | 2005-11-15 | 2014-01-28 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| CA2643796A1 (en) | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | Polycyclic cinnamide derivatives |
| CN101466670B (zh) | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| AU2007239283B2 (en) | 2006-04-18 | 2013-02-07 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor delta |
| US8653115B2 (en) | 2006-06-13 | 2014-02-18 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents |
| CN100503571C (zh) | 2006-07-12 | 2009-06-24 | 中国药科大学 | 四氢异喹啉类衍生物、其制备方法及其医药用途 |
| JP5254228B2 (ja) | 2006-07-27 | 2013-08-07 | 株式會社アモーレパシフィック | バニロイド受容体アンタゴニストとしての、新規化合物、その異性体またはその薬学的に許容される塩；並びにそれを含む医薬組成物 |
| ATE532770T1 (de) | 2006-09-05 | 2011-11-15 | Kyowa Hakko Kirin Co Ltd | Imidazolderivat |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP2124927A2 (en) | 2007-02-26 | 2009-12-02 | Kosan Biosciences Incorporated | Carbamate compounds |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| WO2009003921A1 (en) * | 2007-07-04 | 2009-01-08 | Neurosearch A/S | Novel pyrazole derivatives useful as potassium channel modulators |
| CN102480969A (zh) | 2009-07-09 | 2012-05-30 | 科锐医疗有限公司 | 伤口愈合和瘢痕调制方法 |
| US8518968B2 (en) * | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| WO2011109799A1 (en) * | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| CA2824808A1 (en) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| PL2736887T3 (pl) | 2011-07-29 | 2018-03-30 | Karyopharm Therapeutics, Inc. | Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania |
| BR112014001933A2 (pt) | 2011-07-29 | 2017-02-21 | Karyopharm Therapeutics Inc | moduladores de transporte nuclear e usos dos mesmos |
| WO2013020024A2 (en) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| PT2858991T (pt) | 2012-05-09 | 2018-12-17 | Biogen Ma Inc | Moduladores do transporte nuclear e usos dos mesmos |
| WO2014152263A1 (en) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Exo olefin-containing nuclear transport modulators and uses thereof |
| WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| RS58581B1 (sr) | 2013-06-21 | 2019-05-31 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori jedarnog transporta i njihova primena |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US11567063B2 (en) | 2013-11-15 | 2023-01-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods for assessing cell viability or predicting cell response to a treatment using cell movement |
| WO2016015598A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| CN111484483B (zh) | 2014-08-15 | 2023-05-26 | 卡尔约药物治疗公司 | 赛灵克斯的多晶型物 |
| WO2017117535A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US11034675B2 (en) | 2016-01-08 | 2021-06-15 | Dr. Reddy's Laboratories Limited | Solid forms of Selinexor and process for their preparation |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| WO2018129227A1 (en) | 2017-01-05 | 2018-07-12 | Watson Laboratories Inc. | Novel crystalline forms of selinexor and process for their preparation |
-
2013
- 2013-05-09 PT PT13779943T patent/PT2858991T/pt unknown
- 2013-05-09 JP JP2015511713A patent/JP6195909B2/ja active Active
- 2013-05-09 DK DK18164757.9T patent/DK3404027T3/da active
- 2013-05-09 UA UAA201710733A patent/UA124922C2/uk unknown
- 2013-05-09 SI SI201331239T patent/SI2858991T1/sl unknown
- 2013-05-09 EP EP18164757.9A patent/EP3404027B1/en active Active
- 2013-05-09 HU HUE18164757A patent/HUE050452T2/hu unknown
- 2013-05-09 ES ES13779943T patent/ES2702279T3/es active Active
- 2013-05-09 KR KR1020207008665A patent/KR102163377B1/ko active Active
- 2013-05-09 KR KR1020147034556A patent/KR102095429B1/ko active Active
- 2013-05-09 SI SI201331730T patent/SI3404027T1/sl unknown
- 2013-05-09 ME MEP-2020-110A patent/ME03795B/me unknown
- 2013-05-09 RS RS20200639A patent/RS60424B1/sr unknown
- 2013-05-09 SG SG11201407268SA patent/SG11201407268SA/en unknown
- 2013-05-09 CA CA2872190A patent/CA2872190C/en active Active
- 2013-05-09 EP EP13779943.3A patent/EP2858991B1/en active Active
- 2013-05-09 DK DK13779943.3T patent/DK2858991T3/en active
- 2013-05-09 LT LTEP13779943.3T patent/LT2858991T/lt unknown
- 2013-05-09 US US14/399,868 patent/US9266843B2/en active Active
- 2013-05-09 PE PE2014001997A patent/PE20150128A1/es active IP Right Grant
- 2013-05-09 KR KR1020207028485A patent/KR102223028B1/ko active Active
- 2013-05-09 GE GEAP201313653A patent/GEP20237477B/en unknown
- 2013-05-09 PL PL18164757T patent/PL3404027T3/pl unknown
- 2013-05-09 KR KR1020207028180A patent/KR20200115688A/ko not_active Ceased
- 2013-05-09 HU HUE13779943A patent/HUE040427T2/hu unknown
- 2013-05-09 PL PL13779943T patent/PL2858991T3/pl unknown
- 2013-05-09 PT PT181647579T patent/PT3404027T/pt unknown
- 2013-05-09 SM SM20180686T patent/SMT201800686T1/it unknown
- 2013-05-09 NZ NZ702663A patent/NZ702663A/en unknown
- 2013-05-09 US US13/891,044 patent/US9096543B2/en active Active
- 2013-05-09 MX MX2014013551A patent/MX364992B/es active IP Right Grant
- 2013-05-09 AU AU2013259384A patent/AU2013259384B2/en active Active
- 2013-05-09 SM SM20200347T patent/SMT202000347T1/it unknown
- 2013-05-09 CN CN201380036570.XA patent/CN104428295B/zh active Active
- 2013-05-09 WO PCT/US2013/040404 patent/WO2013170068A2/en not_active Ceased
- 2013-05-09 RS RS20181360A patent/RS58058B1/sr unknown
- 2013-05-09 LT LTEP18164757.9T patent/LT3404027T/lt unknown
- 2013-05-09 EP EP20153455.9A patent/EP3663291B1/en active Active
- 2013-05-09 EA EA201492050A patent/EA036639B1/ru unknown
- 2013-05-09 UA UAA201413015A patent/UA118085C2/uk unknown
- 2013-05-09 KR KR1020207008661A patent/KR102165177B1/ko active Active
- 2013-05-09 BR BR112014027860A patent/BR112014027860B8/pt active IP Right Grant
- 2013-05-09 HR HRP20181838TT patent/HRP20181838T1/hr unknown
- 2013-05-09 ES ES18164757T patent/ES2794866T3/es active Active
- 2013-05-09 IN IN9434DEN2014 patent/IN2014DN09434A/en unknown
- 2013-05-09 ES ES20153455T patent/ES3016982T3/es active Active
-
2014
- 2014-11-10 CL CL2014003054A patent/CL2014003054A1/es unknown
- 2014-11-21 CO CO14256418A patent/CO7190242A2/es unknown
-
2015
- 2015-06-23 US US14/747,394 patent/US9861614B2/en active Active
-
2016
- 2016-01-06 US US14/989,377 patent/US9585874B2/en active Active
- 2016-09-01 AU AU2016222459A patent/AU2016222459A1/en not_active Abandoned
-
2017
- 2017-01-24 US US15/413,889 patent/US10058535B2/en active Active
- 2017-08-23 JP JP2017160341A patent/JP2018012715A/ja not_active Withdrawn
- 2017-12-04 US US15/831,048 patent/US10335393B2/en active Active
-
2018
- 2018-02-12 AU AU2018201012A patent/AU2018201012B2/en active Active
- 2018-07-17 US US16/037,798 patent/US10617677B2/en active Active
- 2018-08-20 JP JP2018154275A patent/JP2018172444A/ja not_active Withdrawn
- 2018-11-08 CY CY181101176T patent/CY1120832T1/el unknown
-
2019
- 2019-05-16 US US16/414,479 patent/US10722497B2/en active Active
- 2019-11-15 JP JP2019206852A patent/JP6818849B2/ja active Active
- 2019-11-28 AU AU2019272017A patent/AU2019272017B2/en active Active
-
2020
- 2020-04-06 US US16/840,841 patent/US10925859B2/en active Active
- 2020-06-02 HR HRP20200876TT patent/HRP20200876T1/hr unknown
- 2020-06-02 CY CY20201100517T patent/CY1123476T1/el unknown
- 2020-08-07 ZA ZA2020/04892A patent/ZA202004892B/en unknown
- 2020-12-28 JP JP2020218700A patent/JP2021063104A/ja not_active Withdrawn
-
2021
- 2021-02-19 US US17/179,512 patent/US11318120B2/en active Active
- 2021-08-23 AU AU2021221398A patent/AU2021221398B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020037585A5 (OSRAM) | ||
| JP2015516434A5 (OSRAM) | ||
| JP2020507589A5 (OSRAM) | ||
| JP2017527578A5 (OSRAM) | ||
| US20080182845A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2004525150A5 (OSRAM) | ||
| JP2019509276A5 (OSRAM) | ||
| JP2015509534A5 (OSRAM) | ||
| JP2013010792A5 (OSRAM) | ||
| JP2019527233A5 (OSRAM) | ||
| JP2017504631A5 (OSRAM) | ||
| JP2017526716A5 (OSRAM) | ||
| JP2017531619A5 (OSRAM) | ||
| JP2019510027A5 (OSRAM) | ||
| JP2007522142A5 (OSRAM) | ||
| JP2004517049A5 (OSRAM) | ||
| JP2020502047A5 (OSRAM) | ||
| JP2015511609A5 (OSRAM) | ||
| JP2019535723A5 (OSRAM) | ||
| JP2019527234A5 (OSRAM) | ||
| CN113825754A (zh) | 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂 | |
| JP2018522861A5 (OSRAM) | ||
| JP2005508337A5 (OSRAM) | ||
| JP2019501879A5 (OSRAM) | ||
| CN115315423A (zh) | 取代芳基类化合物 |